Latest Breaking News On - Accuragen inc - Page 12 : vimarsana.com

Global Cancer Molecular Diagnostics Markets 2021-2025 - New Diagnostics Create New Markets

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report. the publisher includes a special segment, Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Working against this dynamic market are the forces of the COVID Driven Recession. The publisher s latest numbers factor in the different COVID forces, their timing, and their effect on growth.

New yorkUnited statesMiltenyi biotecYourgene elucigeneQiagen gmbhSysmex inosticsBristol myers squibbSiemens healthineersLaura woodAcademic research labTesting labMdx companion dx developmentPublic nationalTechnology developmentUs medicare expenditures for laboratory testingPhysician lab

Global Cancer Genomic Cancer Panel and Profiling (Germline/Somatic) Markets to 2025: Factors Driving Growth - Level of Care, Companion Dx, Immuno-oncology, Liability, Aging Population

Global Cancer Genomic Cancer Panel and Profiling (Germline/Somatic) Markets to 2025: Factors Driving Growth - Level of Care, Companion Dx, Immuno-oncology, Liability, Aging Population
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesPerkin elmerMiltenyi biotecYourgene elucigeneSiemens healthineersQiagen gmbhSysmex inosticsLaura woodAcademic research labTesting labPublic nationalCentral labTechnology developmentSinglera genomics incInvitae corporationPhysician office lab

Global Companion Diagnostic Markets Report 2021-2025: Level of Care, Immuno-oncology, Liability & Aging Population Driving Growth

Will Personalized Companion Diagnostics become the norm for diagnostics? Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market. Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

United statesMiltenyi biotecQiagen gmbhSysmex inosticsBristol myers squibbCdx therascreenSiemens healthineersLaura woodAcademic research labCastle biosciences incTesting labPublic nationalCentral labTechnology developmentSinglera genomics incEndpoint health

Global Liquid Biopsy Markets Report 2021-2025 - Liquid Biopsy Progress Delayed by COVID Pandemic but Huge Cancer Screening Opportunity Still Looms

3.3.2 Bioinformatics Plays a Role 3.4 Diagnostic Technology Development 3.4.2 Impact of NGS on pricing 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment 3.4.4 CGES Testing, A Brave New World 3.4.5 Biochips/Giant magnetoresistance based assay 4. Liquid Biopsy Recent Developments 4.1 Recent Developments - Importance and How to Use This Section 4.1.1 Importance of These Developments 4.1.2 How to Use This Section Liquid Biopsy NGS Panels - Diverse Test Claims CMS Colon Cancer Screening Memo Bodes Well for Assays Natera Liquid Biopsy Test Coverage to Expand Freenome Closes Financing to Support Early Cancer Detection Trial C$2.6M Liquid Biopsy Initiative NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy Liquid Biopsy Shows Promise as Screen for Cancers

Miltenyi biotecSiemens healthineersQiagen gmbhSysmex inosticsLaura woodAcademic research labTesting labPublic nationalCentral labTechnology developmentSinglera genomics incPhysician labPhysician office labM liquid biopsy initiativeEnzo life sciences incOffice hours call

Liquid Biopsy Markets, 2025 with Impact of COVID-19 Pandemic

Liquid Biopsy Markets, 2025 with Impact of COVID-19 Pandemic February 02, 2021 04:43 ET | Source: Research and Markets Research and Markets Dublin, IRELAND ResearchAndMarkets.com s offering. The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring. The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? This report provides a detailed analysis. Circulating Tumor Cells? Cell-Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and pitfalls. Understand growth expectations and the ultimate potential market s

Miltenyi biotecSiemens healthineersQiagen gmbhSysmex inosticsLaura woodAcademic research labTesting labPublic nationalCentral labTechnology developmentSinglera genomics incPhysician labPhysician office labM liquid biopsy initiativeEnzo life sciences incOffice hours call